Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Eligible patients will be post-menopausal hormone receptor- and lymph node-positive females who recently underwent primary surgery for breast cancer. Patients will be randomized to letrozole (2.5 mg per day for 5 years) vs anastrozole (1 mg per day for 5 years). Follow up will occur for 5 years after the completion of enrollment for survival and disease status updates.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Fort Meyers, Florida 33901, United States
Vancover, Washington 98664, United States
Redcliff, Queensland 4020, Australia
East Bentleigh, Victoria 3165, Australia
Franston, Victoria 3199, Australia
Auckland, Australia
Dunedin, Australia
Périgueux Cédex, 24004, France
Antella - Bagno A Ripoli, FI 50011, Italy
Kitaadachi-gun, Saitama 362-0806, Japan
Bunkyo-ku, Tokyo 113-8677, Japan
Chuo-ku, Tokyo 104-0045, Japan
Chuo-ku, Tokyo 104-8560, Japan
Koto, Tokyo 135-8550, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Merseyside, L63 4JY, United Kingdom
Sheffiled, S10 2SJ, United Kingdom
Surrey, SM2 5PT, United Kingdom